Drug Discovery World

SEPTEMBER 26, 2022

It’s why pharmaceutical companies will often spend up to 10 years and upwards of $1 billion before receiving regulatory approval for a drug. This is a stark contrast to the often decade-long projects that pharmaceutical companies undertake to bring a drug to market. Diving into data . Global efforts .

Pharmaceutical Companies 130

Pharmaceutical Companies Drugs Pharmaceuticals Clinical Trials 130

Drug Discovery World

AUGUST 3, 2023

Even still, these approved drug products require a licensed healthcare provider’s prescription. There are also three synthetic cannabis-related drug products, which are Marinol (dronabinol), Syndros (dronabinol), and Cesamet (nabilone).

Clinical Trials 130

Clinical Trials Regulations Production FDA 130

Practical Cheminformatics

DECEMBER 7, 2023

It is rare for graduate students to be exposed to tasks like optimizing pharmacokinetics or off-target binding. When someone joins a drug discovery company from academia, they are often paired with more experienced colleagues. It should be noted that not all biotechs skimp on software licenses. You’ll be glad you did.

Computational Chemistry 90

Computational Chemistry Pharmacokinetics Pharmaceutical Companies Drugs 90

The Pharma Data

AUGUST 21, 2020

Fortunately, as a member of the Novartis Business Development & Licensing (BD&L) department, she was in a position to try to help. After focusing on antimicrobial research for years, Leeds now heads a BD&L effort that builds relationships and collaborations with companies on the West Coast of the US and across all of Canada.

Virus 52

Virus Small Molecule Licensing Licensing 52

The Pharma Data

AUGUST 19, 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANT TM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations.

Treatment 52

Treatment FDA Approval Pharmacokinetics FDA 52

The Pharma Data

NOVEMBER 6, 2020

With the opinions expressed at the Advisory Committee and the data presented, the FDA will continue the review process with a decision on whether to approve the aducanumab Biologics License Application by March 7, 2021. . Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement.

Disease 40

Disease FDA Clinical Trials Licensing 40

The Pharma Data

OCTOBER 27, 2020

Impairment of investment in privately-held company (2). Unrealized gain on investment in privately-held company (3). License-related fees (5). License-related fees (5). 2020.

FDA 40

FDA Production Licensing Licensing 40